Avodart Cost in Connecticut 2026: Dutasteride Prices, Insurance & Medicaid Guide

What Is Avodart and Why Does It Cost So Much at List Price?

Dutasteride (brand name Avodart, manufactured by GSK) is a dual 5-alpha reductase inhibitor that blocks both type 1 and type 2 isoenzymes, reducing serum dihydrotestosterone (DHT) by approximately 90% at the standard 0.5 mg daily dose. The FDA approved Avodart for benign prostatic hyperplasia in November 2001 [1]. Generic dutasteride became available in the United States after patent expiration, and that competition is the single biggest reason cash-pay prices have fallen so far below the brand list price of roughly $290 per month.

The FDA's prescribing label for Avodart specifies the approved indication, dosage, and contraindications that any Connecticut prescriber must follow [1]. Dutasteride is classified as a Pregnancy Category X drug, meaning it must never be handled by women who are or may become pregnant, and Connecticut pharmacists routinely counsel male patients on this point at dispensing. The capsules should be swallowed whole because contact with the liquid contents can be absorbed through skin.

Generic manufacturers including Zydus, Mylan (now Viatris), and Teva have produced dutasteride 0.5 mg capsules since the mid-2010s. Price competition among these manufacturers drives the Connecticut retail cash-pay average to around $25 per month for a 30-capsule supply in 2026, a reduction of more than 90% from the brand list price [2]. The AERS database at FDA continues to track post-market safety signals for both brand and generic formulations [1].

Dutasteride Prices at Connecticut Pharmacies in 2026

Generic dutasteride 0.5 mg (30 capsules, one month supply) costs approximately $20 to $35 cash pay at major Connecticut retail chains in 2026. CVS locations across Hartford, New Haven, Bridgeport, and Stamford typically price the generic at $22 to $28 without any discount card. Walgreens Connecticut stores fall in a similar range. Independent pharmacies vary more widely, sometimes pricing the same supply at $30 to $40 before discounts.

GoodRx coupons applied at Connecticut pharmacies can bring the price to $18 to $24 at participating locations, depending on which chain honors the coupon tier that month [3]. The FDA has noted that pharmacy benefit manager negotiations and coupon programs are distinct from insurance coverage, meaning a GoodRx coupon does not apply toward a deductible [1]. Patients who are working toward a deductible reset may prefer to use insurance even when the out-of-pocket cost is similar.

Brand-name Avodart at Connecticut pharmacies still carries the manufacturer's list price near $290 for 30 capsules when billed without insurance. Almost no cash-pay patient has a clinical reason to choose brand over generic, because the FDA requires generic manufacturers to demonstrate bioequivalence [4]. The FDA's Orange Book confirms therapeutic equivalence ratings for dutasteride generics currently marketed in the United States [4].

A 90-day supply (90 capsules) purchased through mail-order pharmacy programs or warehouse clubs like Costco can reduce the per-capsule cost further, sometimes reaching an effective price of $15 to $18 per month equivalent. Costco's pharmacy has no membership requirement for prescription purchases in Connecticut under state law [5].

Connecticut Medicaid Coverage for Dutasteride (Avodart)

Connecticut Medicaid (HUSKY Health) covers dutasteride for BPH with prior authorization. The prior authorization process requires the prescribing clinician to document that the patient has a confirmed BPH diagnosis, typically supported by an International Prostate Symptom Score (IPSS) assessment, a digital rectal exam finding, or urological imaging showing prostate enlargement. The Connecticut Department of Social Services administers HUSKY Health and publishes its preferred drug list updates quarterly [6].

For off-label use in androgenetic alopecia (male pattern hair loss), Medicaid coverage is less predictable. Connecticut Medicaid managed care organizations retain discretion to deny off-label claims that are not supported by a peer-reviewed evidence base meeting their internal criteria. The clinical evidence for dutasteride in androgenetic alopecia is real but the drug remains off-label for that indication in the United States, which affects Medicaid reimbursement decisions [7].

Eun et al. (J Am Acad Dermatol, 2010, N=153) conducted a randomized controlled trial comparing dutasteride 0.5 mg daily to finasteride 1 mg daily in men with androgenetic alopecia over 24 weeks. Dutasteride produced significantly greater improvement in target area hair count (P<0.001) compared to finasteride, though neither drug carries an FDA approval for this use in the United States [7]. Connecticut Medicaid reviewers will typically require documentation of prior finasteride failure before considering PA approval for dutasteride in alopecia, if they consider it at all.

Patients enrolled in HUSKY Health D (the low-income adult expansion population) follow the same PA pathway as HUSKY Health A enrollees for BPH indications. Connecticut's Medicaid preferred drug list designates dutasteride as a preferred agent in the 5-alpha reductase inhibitor class when prior authorization criteria are met [6].

Is Compounded Dutasteride Legal in Connecticut?

Yes. Compounded dutasteride is legal in Connecticut when prepared by a licensed 503A compounding pharmacy operating under Connecticut state pharmacy law and the federal Drug Quality and Security Act (DQSA) [8]. A 503A pharmacy compounds medications for individual patients pursuant to a valid prescription from a licensed prescriber. Connecticut's Department of Consumer Protection, Drug Control Division, licenses and inspects compounding pharmacies operating within the state [9].

503A pharmacies can formulate dutasteride in custom strengths, alternative bases (such as topical solutions for scalp application, though evidence for topical dutasteride absorption varies), or in combination with other compounds when a prescriber documents a patient-specific clinical need. The FDA distinguishes 503A compounding (patient-specific, prescription-required) from 503B outsourcing facilities (large-batch, hospital-supply model); both operate legally under federal law, but only 503A covers the individualized prescriptions typical in Connecticut telehealth or dermatology practice [8].

Compounded oral dutasteride capsules from Connecticut-licensed 503A pharmacies run approximately $40 per month in 2026. That is higher than generic retail ($25/month) but may offer dose flexibility that commercially available 0.5 mg capsules cannot. Some hair-loss specialists prescribe 0.5 mg daily for BPH-related use and 0.5 mg every other day for androgenetic alopecia maintenance, a schedule that commercial packaging does not optimize for. Compounding also allows patients with documented inactive ingredient sensitivities to obtain a reformulated capsule.

The National Academies of Sciences, Engineering, and Medicine published a 2020 report on pharmacy compounding that described the regulatory boundary between 503A and 503B facilities and the patient safety considerations that govern both [10]. Connecticut prescribers and patients should verify that any pharmacy filling a compounded dutasteride prescription holds an active Connecticut state license, which is verifiable through the DCP online license lookup tool [9].

Insurance Coverage for Avodart in Connecticut

Most commercial insurance plans sold in Connecticut, including those offered through Access Health CT (the state exchange), cover generic dutasteride for BPH under their formularies. The Affordable Care Act requires exchange plans to cover prescription drugs, and dutasteride appears on Tier 2 or Tier 3 formulary positions in the majority of silver and gold plans reviewed for the 2026 plan year [11].

Employer-sponsored plans administered by Aetna, Cigna, UnitedHealthcare, and Anthem Blue Cross Blue Shield of Connecticut typically place generic dutasteride on Tier 2 (preferred generic), resulting in a copay of $10 to $30 per 30-day fill depending on plan design. Tier placement and specific copays vary by employer contract, so patients should confirm their specific plan's drug benefit through their insurer's online formulary tool or by calling the member services number on their insurance card.

Brand-name Avodart is placed on Tier 3 or Tier 4 in virtually all Connecticut commercial plans, meaning the cost-sharing is substantially higher, sometimes $80 to $150 or more per fill even with coverage. Because the FDA has established therapeutic equivalence between brand and generics [4], step-therapy requirements at most Connecticut insurers require a trial of generic before brand will be covered, if brand coverage exists at all.

Medicare Part D plans available to Connecticut beneficiaries also cover dutasteride. The standard 2026 Part D benefit structure means beneficiaries pay their plan's copay or coinsurance, and the Inflation Reduction Act's $2,000 out-of-pocket cap on Part D costs provides a ceiling for high-cost drug years [12]. At roughly $25/month generic cash-pay pricing, most Connecticut Medicare patients will not reach the catastrophic threshold on dutasteride alone, but the cap still provides protection for those taking multiple drugs.

How to Get Dutasteride via Telehealth in Connecticut

Connecticut law permits telehealth prescribing of dutasteride by licensed Connecticut prescribers or out-of-state prescribers holding a Connecticut telehealth registration. The Connecticut Medical Practice Act, as amended through the telehealth provisions enacted in 2021 (Public Act 21-133), authorizes audio-video and, in some circumstances, audio-only consultations for prescription of non-controlled substances including dutasteride [13].

A valid patient-provider relationship must be established before a telehealth prescriber issues a dutasteride prescription in Connecticut. For BPH, that typically means a structured symptom history using IPSS criteria and documentation of relevant physical findings, which some telehealth platforms satisfy through structured intake questionnaires reviewed by a physician or advanced practice provider. Telehealth platforms serving Connecticut patients include general-purpose services (Teladoc, MDLive) and specialty men's health platforms.

HealthRX clinicians conduct synchronous video consultations that satisfy the Connecticut standard for establishing a prescribing relationship. After a consultation confirming eligibility, the prescription routes to the patient's preferred Connecticut pharmacy or a mail-order partner, typically arriving within two business days.

For hair-loss indications, the American Academy of Dermatology's 2021 guidelines on androgenetic alopecia note that 5-alpha reductase inhibitors are an evidence-based treatment option for male patients, and that dutasteride has demonstrated superiority over finasteride in hair count outcomes in controlled trials [7][14]. A telehealth dermatology or men's health consultation can address both BPH and alopecia indications, depending on the patient's clinical profile.

The Cheapest Way to Get Dutasteride in Connecticut in 2026

The lowest reliable price for dutasteride in Connecticut in 2026 is generic dutasteride 0.5 mg purchased cash pay with a GoodRx or similar coupon, running $18 to $24 per 30-day supply at Hartford, New Haven, or Stamford pharmacies. A 90-day supply through Costco Pharmacy (no membership required for prescriptions in Connecticut) can bring the monthly equivalent to approximately $15 to $18 [5][3].

The HealthRX cost-minimization framework for Connecticut dutasteride patients in 2026 applies these steps in sequence:

1. Confirm generic availability at the target pharmacy (all major Connecticut chains stock dutasteride generics).
2. Check GoodRx, RxSaver, and NeedyMeds coupon tiers for the specific pharmacy ZIP code, prices vary by ZIP even within the same chain [3][15].
3. Request a 90-day supply to reduce per-unit dispensing fees.
4. If insured, compare the insurance copay to the cash-pay GoodRx price; take whichever is lower (insurers cannot prohibit this in Connecticut as of 2026).
5. If Medicaid-eligible, submit BPH documentation through the PA pathway to obtain $0 or minimal cost-share coverage [6].
6. If a compounded formulation is medically necessary (documented intolerance to commercial excipients or non-standard dose), a Connecticut 503A pharmacy at approximately $40/month remains a legal and accessible option [8].

Manufacturer patient assistance programs (PAPs) historically offered by GSK for brand Avodart are less relevant given generic pricing but remain available for patients who specifically require the brand due to documented generic intolerance [16]. GSK's US patient assistance program eligibility is income-based and requires annual recertification [16].

Side Effects and Monitoring That Affect Long-Term Cost

Dutasteride's cost picture includes not only the drug price but also the monitoring visits and any management of adverse effects. The most common adverse effects reported in clinical trials are sexual in nature: decreased libido (approximately 5 to 6% in ARIA and REDUCE trials), erectile dysfunction (approximately 5%), ejaculation disorders (approximately 2%), and gynecomastia (approximately 1%) [17][18]. These are generally dose-independent and may persist after discontinuation in a subset of patients.

The REDUCE trial (N=8,231 to 4 years, dutasteride 0.5 mg vs. placebo) found a 22.8% relative reduction in prostate biopsy-detected prostate cancer over 4 years, though an increased rate of high-grade tumors (Gleason 8 to 10) in the dutasteride arm led the FDA to issue a safety communication and decline approval of dutasteride for chemoprevention [17][19]. Connecticut prescribers discussing dutasteride for BPH or alopecia should document this FDA communication in their informed consent process [19].

PSA monitoring is standard practice: dutasteride reduces PSA by approximately 50% within 6 months of starting therapy [1]. Connecticut clinicians must double the observed PSA value to estimate the true underlying level for prostate cancer screening purposes, as recommended in the Avodart prescribing information and by the American Urological Association guidelines [20]. A baseline PSA before starting dutasteride and a follow-up at 6 months adds two lab visits to the annual cost picture, typically covered under preventive or office visit benefits by Connecticut commercial insurers.

Dutasteride vs. Finasteride in Connecticut: Cost and Clinical Comparison

Finasteride 1 mg (Propecia brand, for hair loss) and finasteride 5 mg (Proscar brand, for BPH) are the main clinical alternatives to dutasteride in Connecticut. Generic finasteride 5 mg runs approximately $10 to $15 per month cash pay at Connecticut pharmacies in 2026, making it cheaper than generic dutasteride by roughly $10 per month [3].

The clinical trade-off is DHT suppression depth. Finasteride inhibits only the type 2 isoenzyme, reducing DHT by approximately 70%, while dutasteride's dual inhibition reduces DHT by approximately 90% [21]. For patients with aggressive BPH symptoms or those who have failed finasteride for alopecia, the additional DHT suppression of dutasteride may justify the modest price difference.

The American Urological Association's 2021 BPH guidelines state that "5-alpha reductase inhibitors are recommended for patients with LUTS/BPH and prostates estimated to be >30 mL or PSA >1.5 ng/mL," without specifying dutasteride over finasteride, leaving the choice to clinical and patient preference [20]. The 10-dollar monthly price difference is unlikely to be the deciding factor for most insured Connecticut patients, but it matters for uninsured patients managing costs carefully.

The CombAT trial (N=4,844 to 4 years) compared dutasteride monotherapy, tamsulosin monotherapy, and combination therapy, finding the combination produced greater symptom relief than either drug alone at 4 years, with a 66% reduction in the risk of acute urinary retention compared to tamsulosin monotherapy [22]. Connecticut prescribers managing moderate-to-severe BPH often combine dutasteride with an alpha-blocker (tamsulosin, $5 to $10/month generic in Connecticut), adding to the total monthly drug cost but improving clinical outcomes [22].